First-in-human results prompt a biomarker-defined approach for CID-078.
ApexOnco Front Page
Recent articles
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
